Table 4 Warfarin indication among outpatients compared between UMC and PLAC
Indication of warfarin | Total (N = 525) n(%) | UMC Group (N = 350) n %) | PLAC Group (N = 175) n (%) | P-value |
|---|---|---|---|---|
Atrial fibrillation | 335 (63.8) | 210 (60.0) | 125 (71.4) | 0.01 |
Valvular heart disease | 59 (11.2) | 46 (13.1) | 13 (7.4) | 0.05 |
Cardioembolisma | 49 (9.3) | 33 (9.4) | 16 (9.1) | 0.92 |
Post heart valves (mechanical)c | 84 (16.0) | 44 (12.6) | 40 (22.9) | 0.002 |
Cardiac Thrombusb | 18 (3.4) | 10 (2.9) | 8 (4.6) | 0.31 |
(Bio) prosthetic valve replacement/ repairc | 22 (4.2) | 8 (2.3) | 14 (8.0) | 0.002 |
Post-percutaneous mitral balloon valvotomyc | 27 (5.1) | 12 (3.4) | 15 (8.6) | 0.012 |
Cardiomyopathyc | 10 (1.9) | 4 (1.1) | 6 (3.4) | 0.091 |
IHD with thrombus | 10 (1.9) | 4 (1.1) | 6 (3.4) | 0.091 |
Deep vein thrombosis | 37 (7.0) | 37 (10.6) | 0 (0) |  < 0.001 |
Pulmonary embolism | 7 (2.0) | 7 (2.0) | 0 (0) | 0.102 |
Portal vein thrombosis | 11 (2.1) | 11 (3.1) | 0 (0) | 0.019 |